560 related articles for article (PubMed ID: 9486096)
1. Reflections on the development of resistance during therapy for advanced breast cancer. Implications of high levels of activity of docetaxel in anthracycline-resistant breast cancer patients.
Ravdin PM
Eur J Cancer; 1997 Aug; 33 Suppl 7():S7-10. PubMed ID: 9486096
[TBL] [Abstract][Full Text] [Related]
2. Docetaxel (Taxotere) for the treatment of anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-18-S10-21. PubMed ID: 9275002
[TBL] [Abstract][Full Text] [Related]
3. Taxoids: effective agents in anthracycline-resistant breast cancer.
Ravdin PM
Semin Oncol; 1995 Dec; 22(6 Suppl 13):29-34. PubMed ID: 8604450
[TBL] [Abstract][Full Text] [Related]
4. Vinorelbine and cisplatin for metastatic breast cancer: a salvage regimen in patients progressing after docetaxel and anthracycline treatment.
Vassilomanolakis M; Koumakis G; Demiri M; Missitzis J; Barbounis V; Efremidis AP
Cancer Invest; 2003; 21(4):497-504. PubMed ID: 14533438
[TBL] [Abstract][Full Text] [Related]
5. Emerging role of taxanes in adjuvant and neoadjuvant therapy for breast cancer: the potential and the questions.
Goble S; Bear HD
Surg Clin North Am; 2003 Aug; 83(4):943-71. PubMed ID: 12875604
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer.
Ravdin PM; Burris HA; Cook G; Eisenberg P; Kane M; Bierman WA; Mortimer J; Genevois E; Bellet RE
J Clin Oncol; 1995 Dec; 13(12):2879-85. PubMed ID: 8523050
[TBL] [Abstract][Full Text] [Related]
7. Emerging role of docetaxel (Taxotere) in the adjuvant therapy of breast cancer.
Ravdin PM
Semin Oncol; 1999 Jun; 26(3 Suppl 9):20-3. PubMed ID: 10426455
[TBL] [Abstract][Full Text] [Related]
8. The current status of docetaxel for metastatic breast cancer.
Esteva FJ
Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
[TBL] [Abstract][Full Text] [Related]
9. Paclitaxel-induced remission in docetaxel-refractory anthracycline-pretreated metastatic breast cancer.
Suzuma T; Sakurai T; Yoshimura G; Umemura T; Tamaki T; Naito Y
Anticancer Drugs; 2000 Aug; 11(7):569-71. PubMed ID: 11036960
[TBL] [Abstract][Full Text] [Related]
10. Single-agent docetaxel (Taxotere) in randomized phase III trials.
Burris HA
Semin Oncol; 1999 Jun; 26(3 Suppl 9):1-6. PubMed ID: 10426452
[TBL] [Abstract][Full Text] [Related]
11. Evolution in the treatment of advanced breast cancer.
Crown J
Semin Oncol; 1998 Oct; 25(5 Suppl 12):12-7. PubMed ID: 9865706
[TBL] [Abstract][Full Text] [Related]
12. Prospects with docetaxel in the treatment of patients with breast cancer.
Marty M; Extra JM; Cottu PH; Espié M
Eur J Cancer; 1997 Aug; 33 Suppl 7():S26-9. PubMed ID: 9486101
[TBL] [Abstract][Full Text] [Related]
13. Docetaxel and paclitaxel in breast cancer therapy: present status and future prospects.
D'Andrea GM; Seidman AD
Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-27-S13-44. PubMed ID: 9335514
[TBL] [Abstract][Full Text] [Related]
14. Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer.
Brodowicz T; Koestler WJ; Tomek S; Vaclavik I; Herscovici V; Wiltschke C; Steger GG; Zielinski CC
Anticancer Drugs; 2000 Mar; 11(3):149-53. PubMed ID: 10831273
[TBL] [Abstract][Full Text] [Related]
15. A review of the efficacy and safety of docetaxel as monotherapy in metastatic breast cancer.
Crown J
Semin Oncol; 1999 Feb; 26(1 Suppl 3):5-9. PubMed ID: 10203264
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
[TBL] [Abstract][Full Text] [Related]
17. Docetaxel in anthracycline-resistant metastatic breast cancer.
Hui YF; Ignoffo RJ
Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
[TBL] [Abstract][Full Text] [Related]
18. Single-agent docetaxel in metastatic breast cancer patients pre-treated with anthracyclines and paclitaxel: partial cross-resistance between paclitaxel and docetaxel.
Lin YC; Chang HK; Wang CH; Chen JS; Liaw CC
Anticancer Drugs; 2000 Sep; 11(8):617-21. PubMed ID: 11081452
[TBL] [Abstract][Full Text] [Related]
19. Treatment of patients resistant to anthracycline therapy.
Ravdin PM
Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
[TBL] [Abstract][Full Text] [Related]
20. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
Pivot X; Asmar L; Hortobagyi GN
Int J Oncol; 1999 Aug; 15(2):381-6. PubMed ID: 10402251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
